Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
4502 heads into its October 29 earnings release with short sellers in full retreat, borrowing costs near a monthly low, and the stock up 4.3% on the week.
The clearest shift in positioning is in the lending market. Cost to borrow has fallen sharply, dropping around 30% over the past month to 0.83% after spiking as high as 4.36% in late September. That spike looks transient. Availability has swung from tight to extremely loose: the ratio of shares available to borrow against shares already borrowed now stands at 1,764%, the highest reading in the ORTEX 30-day window and well above the 52-week floor of 355%. In practical terms, the lending pool has room for seventeen new shares to be borrowed for every one already out. The ORTEX short score reflects the same reversal, falling from 51 at the start of October to 32 by October 12, its lowest point in the recent series. Borrow conditions have loosened dramatically in the two weeks since late September, and there is no sign of renewed short-building pressure in the data.
The Street remains cautiously constructive. The consensus is a buy, with a mean analyst price target of around 6,622 yen against a current price of 5,963 yen, implying roughly 11% upside. That analyst data is about four weeks old, so treat it as directional rather than precise. Factor scores flesh out the picture: Takeda scores in the 98th percentile on dividend yield, a signal the stock continues to attract income-oriented holders, while its short score rank of 76 (higher meaning more short-selling pressure relative to peers) is worth noting even as the absolute short score has eased. The EV/EBITDA multiple has drifted up modestly, around 10.5x, rising about 0.4 points over the past month as the share price has recovered.
Institutional ownership is broadly stable. BlackRock remains the largest declared holder with around 9.1% of shares, and added roughly 10 million shares in the most recent reporting period ending September 30. Capital Research similarly added about 7.9 million shares over the same window. The moves are incremental rather than transformative, but the direction among the largest foreign holders is modestly positive.
The earnings history carries a note of caution. The July 30 quarterly release produced a one-day decline of 5.7% and a five-day fall of 7.2%. The one prior data point available, from late June, was a gain of less than 1%. That is a thin sample, but the most recent print set a clear pattern of post-results selling, and the stock is heading into October 29 with a stronger price than it had going into July.
The question for October 29 is whether the recovery in the share price, which is up more than 5% over the past month, and the retreat in short interest reflect genuine fundamental improvement, or simply a reversal of the September borrow squeeze that temporarily distorted the lending signal.
See the live data behind this article on ORTEX.
Open 4502 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
